MX2009006310A - Composiciones y metodos para tratar trastornos musculares y cardiovasculares. - Google Patents
Composiciones y metodos para tratar trastornos musculares y cardiovasculares.Info
- Publication number
- MX2009006310A MX2009006310A MX2009006310A MX2009006310A MX2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiovascular disorders
- compositions
- methods
- muscular
- treat muscular
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 3
- 230000003387 muscular Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 208000021642 Muscular disease Diseases 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86993706P | 2006-12-14 | 2006-12-14 | |
| PCT/US2007/025535 WO2008076324A2 (en) | 2006-12-14 | 2007-12-13 | Compositions and methods to treat muscular & cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006310A true MX2009006310A (es) | 2009-07-22 |
Family
ID=39536897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006310A MX2009006310A (es) | 2006-12-14 | 2007-12-13 | Composiciones y metodos para tratar trastornos musculares y cardiovasculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20100280094A1 (https=) |
| EP (1) | EP2104733A2 (https=) |
| JP (3) | JP2010512747A (https=) |
| KR (1) | KR20090098818A (https=) |
| CN (2) | CN101563458A (https=) |
| AU (1) | AU2007334502B2 (https=) |
| BR (1) | BRPI0719995A2 (https=) |
| CA (1) | CA2672606A1 (https=) |
| EA (2) | EA200900782A1 (https=) |
| MX (1) | MX2009006310A (https=) |
| WO (1) | WO2008076324A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101485495B1 (ko) | 2006-08-01 | 2015-01-22 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정 |
| WO2009018492A2 (en) | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | Micro-rnas that control myosin expression and myofiber identity |
| CN102356162A (zh) * | 2009-02-04 | 2012-02-15 | 得克萨斯系统大学董事会 | Mir-208和mir-499在治疗心脏病症中的双重靶向 |
| IE20090047A1 (en) * | 2009-02-26 | 2010-09-29 | Nat Univ Ireland | Protein targets in disease |
| US9034605B2 (en) | 2009-03-12 | 2015-05-19 | Brandeis University | Reagents and methods for PCR |
| EA201370139A1 (ru) | 2010-12-15 | 2013-10-30 | Мираген Терапеутикс | Ингибиторы микро-рнк, содержащие закрытые нуклеотиды |
| WO2013052965A2 (en) | 2011-10-06 | 2013-04-11 | Miragen Therapeutics | Control of whole body energy homeostasis by microrna regulation |
| US9388408B2 (en) | 2012-06-21 | 2016-07-12 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| HK1212597A1 (zh) | 2012-10-15 | 2016-06-17 | Isis Pharmaceuticals, Inc. | 用於調節c90rf72表達的組合物 |
| WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
| WO2014169126A1 (en) * | 2013-04-10 | 2014-10-16 | Reveragen Biopharma, Inc. | Methods and agents to increase therapeutic dystrophin expression in muscle |
| EP4166667A3 (en) | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| CN108064175A (zh) * | 2014-08-04 | 2018-05-22 | 米拉根医疗股份有限公司 | Myh7b的抑制剂及其用途 |
| US9885042B2 (en) | 2015-01-20 | 2018-02-06 | MiRagen Therapeutics, Inc. | miR-92 inhibitors and uses thereof |
| RS60230B1 (sr) | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| CN106148519A (zh) * | 2016-07-05 | 2016-11-23 | 无锡市第二人民医院 | 一种microRNA‑499的快速检测方法 |
| WO2019014656A1 (en) | 2017-07-14 | 2019-01-17 | Han Si Ping | METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| EP3665281A4 (en) * | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY |
| KR102281710B1 (ko) | 2021-02-19 | 2021-07-28 | 조기정 | 에어튜브를 이용한 선박 안전장치 |
| CN119246849B (zh) * | 2024-12-09 | 2025-03-14 | 上海基灵生物科技有限公司 | 一种检测犬心脏损伤的试剂盒及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| ES2083593T3 (es) * | 1990-08-03 | 1996-04-16 | Sterling Winthrop Inc | Compuestos y metodos para inhibir la expresion de genes. |
| US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5700922A (en) * | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| JP3516167B2 (ja) * | 1992-12-08 | 2004-04-05 | ローム株式会社 | タンタルコンデンサチップの製造方法 |
| US6271359B1 (en) * | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| ES2559828T3 (es) * | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| US7521184B2 (en) * | 2003-08-22 | 2009-04-21 | Sirna Therapeutics, Inc. | Detection and quantitation of nucleic acid molecules in biological samples |
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| WO2006107826A2 (en) * | 2005-04-04 | 2006-10-12 | The Board Of Regents Of The University Of Texas System | Micro-rna's that regulate muscle cells |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| EP1984497A2 (en) * | 2006-01-10 | 2008-10-29 | Koninklijke Nederlandse Akademie van Wetenschappen | Nucleic acid molecules and collections thereof, their application and identification |
| KR101485495B1 (ko) * | 2006-08-01 | 2015-01-22 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정 |
| WO2009018492A2 (en) * | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | Micro-rnas that control myosin expression and myofiber identity |
-
2007
- 2007-12-13 AU AU2007334502A patent/AU2007334502B2/en not_active Ceased
- 2007-12-13 MX MX2009006310A patent/MX2009006310A/es not_active Application Discontinuation
- 2007-12-13 EP EP07867751A patent/EP2104733A2/en not_active Withdrawn
- 2007-12-13 EA EA200900782A patent/EA200900782A1/ru unknown
- 2007-12-13 EA EA201101361A patent/EA201101361A1/ru unknown
- 2007-12-13 CN CNA2007800464358A patent/CN101563458A/zh active Pending
- 2007-12-13 JP JP2009541384A patent/JP2010512747A/ja not_active Withdrawn
- 2007-12-13 CA CA002672606A patent/CA2672606A1/en not_active Abandoned
- 2007-12-13 BR BRPI0719995-3A2A patent/BRPI0719995A2/pt not_active IP Right Cessation
- 2007-12-13 KR KR1020097012148A patent/KR20090098818A/ko not_active Withdrawn
- 2007-12-13 CN CN2012100499504A patent/CN102604951A/zh active Pending
- 2007-12-13 WO PCT/US2007/025535 patent/WO2008076324A2/en not_active Ceased
- 2007-12-13 US US12/519,323 patent/US20100280094A1/en not_active Abandoned
-
2011
- 2011-08-09 US US13/206,055 patent/US20120041052A1/en not_active Abandoned
- 2011-08-17 JP JP2011178297A patent/JP2012019789A/ja not_active Withdrawn
-
2012
- 2012-01-18 US US13/352,570 patent/US20120114744A1/en not_active Abandoned
- 2012-02-21 JP JP2012034691A patent/JP2012131812A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090098818A (ko) | 2009-09-17 |
| EP2104733A2 (en) | 2009-09-30 |
| AU2007334502B2 (en) | 2011-12-15 |
| WO2008076324A2 (en) | 2008-06-26 |
| US20120041052A1 (en) | 2012-02-16 |
| EA200900782A1 (ru) | 2009-12-30 |
| CA2672606A1 (en) | 2008-06-26 |
| EA201101361A1 (ru) | 2012-11-30 |
| US20100280094A1 (en) | 2010-11-04 |
| BRPI0719995A2 (pt) | 2014-03-18 |
| JP2012019789A (ja) | 2012-02-02 |
| US20120114744A1 (en) | 2012-05-10 |
| JP2012131812A (ja) | 2012-07-12 |
| AU2007334502A1 (en) | 2008-06-26 |
| WO2008076324A3 (en) | 2009-04-09 |
| CN101563458A (zh) | 2009-10-21 |
| CN102604951A (zh) | 2012-07-25 |
| JP2010512747A (ja) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006310A (es) | Composiciones y metodos para tratar trastornos musculares y cardiovasculares. | |
| MX2020004099A (es) | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. | |
| WO2010017436A3 (en) | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides | |
| WO2010017152A3 (en) | Modulation of toll-like receptor 8 expression by antisense oligonucleotides | |
| WO2009045356A8 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| WO2008137867A3 (en) | Compositions comprising mir34 therapeutic agents for treating cancer | |
| WO2010129746A3 (en) | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| TW200637522A (en) | Skin treatment articles and methods | |
| WO2007095316A3 (en) | Compositions and methods for oligonucleotide formulations | |
| WO2011163499A3 (en) | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna | |
| WO2008104978A3 (en) | Novel sirna structures | |
| MY155418A (en) | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
| WO2010017154A3 (en) | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | |
| TN2009000318A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| MX2007004547A (es) | Inhibidores de quinesina mitotica y metodos de uso de los mismos. | |
| WO2010102058A3 (en) | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 | |
| WO2011103528A3 (en) | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 | |
| WO2011090741A3 (en) | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 | |
| WO2010014572A3 (en) | Modulation of toll-like receptor 9 expression by antisense oligonucleotides | |
| WO2007050587A3 (en) | Therapeutic compositions and methods | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |